NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism

Endocrine

Volumn 45, Issue 3, 2014, Pages 479-486

  Pizzolo, Francesca ^a   Zorzi, Francesco ^a   Chiecchi, Laura ^a   Consoli, Letizia ^a   Aprili, Irene ^a   Guarini, Patrizia ^a   Castagna, Annalisa ^a   Salvagno, Gian Luca ^b   Pavan, Chiara ^a   Olivieri, Oliviero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Diagnosis; Intravenous salt loading test; NT proBNP; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; RENIN; SODIUM CHLORIDE; TRIACYLGLYCEROL; VERAPAMIL; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; HORMONE INHIBITION; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREDICTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; BLOOD; COMPLICATION; DIAGNOSTIC USE; HYPERALDOSTERONISM; MIDDLE AGED; PREDICTIVE VALUE;

ADULT; ALDOSTERONE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RENIN; SEX FACTORS; SODIUM CHLORIDE;

EID: 84897042435     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0028-6     Document Type: Article

References (37)

1. J.W. Funder, R.M. Carey, C. Fardella et al., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266-3281 (2008)
2. M. Stowasser, Update in primary aldosteronism. J. Clin. Endocrinol. Metab. 94, 3623-3630 (2009)
3. N. Sukor, Primary aldosteronism: from bench to bedside. Endocrine 41, 31-39 (2012)
4. L.A. Sechi, G. Colussi, A. Di Fabio, C. Catena, Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am. J. Hypertens. 23, 1253-1260 (2010)
5. R. Rocha, A.E. Rudolph, G.E. Frierdich et al., Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart. Circ. Physiol. 283, H1802-H1810 (2002)
6. Y. Shigematsu, M. Hamada, H. Okayama et al., Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 29, 723-727 (1997)
7. M.L. Muiesan, M. Salvetti, A. Paini et al., Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 52, 529-534 (2008)
8. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243-1248 (2005)
9. C. Catena, G. Colussi, E. Nadalini et al., Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80-85 (2008)
10. B. Pitt, F. Zannad, W.J. Remme et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709-717 (1999)
11. B. Pitt, W. Remme, F. Zannad et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003)
12. F. Zannad, J.J. McMurray, H. Krum et al., Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011)
13. E.R. Levin, D.G. Gardner, W.K. Samson, Natriuretic peptides. N. Engl. J. Med. 339, 321-328 (1998)
14. A.J. De Bold, K.K. Ma, Y. Zhang, M.L. de Bold, M. Bensimon, A. Khoshbaten, The physiological and pathophysiological modulation of the endocrine function of the heart. Can. J. Physiol. Pharmacol. 79, 705-714 (2001)
15. K. Dickstein, A. Cohen-Solal, G. Filippatos et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur. Heart. J. 29, 2388-2442 (2008)
16. M. Richards, M.G. Nicholls, E.A. Espiner et al., Christchurch Cardioendocrine Research Group; Australia-New Zealand Heart Failure Group. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J. Am. Coll. Cardiol. 47, 52-60 (2006)
17. K. Yamamoto, J.C. Burnett, M. Jougasaki, Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28, 988-994 (1996)
18. A.S. Pahle, D. Sørli, T. Omland et al., Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspnea. Am. J. Cardiol. 104, 966-971 (2009)
19. K.K. Gaddam, M.K. Nishizaka, M.N. Pratt-Ubunama et al., Characterization of resistant hypertension: association between resistant hypertension aldosterone and persistent intravascular volume expansion. Arch. Intern. Med. 168, 1159-1164 (2008)
20. Y.J. Lee, S.R. Lin, S.J. Shin, Y.H. Lai, Y.T. Lin, J.H. Tsai, Brain natriuretic peptide is synthesized in the human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 79, 1476-1482 (1994)
21. T.J. Tunny, R.D. Gordon, Plasma atrial natriuretic peptide in primary aldosteronism (before and after treatment) and in Bartter's and Gordon's syndromes. Lancet 1, 272-273 (1986)
22. J. Kato, T. Etoh, K. Kitamura, T. Eto, Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am. J. Hypertens. 18, 354-357 (2005)
23. K. Gaddam, C. Corros, E. Pimenta et al., Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 55, 1137-1142 (2010)
24. T. Tsutamoto, A. Wada, K. Maeda et al., Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37, 1228-1233 (2001)
25. A. Boccanelli, G.F. Mureddu, G. Cacciatore et al., AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur. J. Heart Fail. 11, 68-76 (2009)
26. O.B. Holland, H. Brown, L. Kuhnert, C. Fairchild, M. Risk, C.E. Gomez-Sanchez, Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 6, 717-723 (1984)
27. P. Mulatero, A. Milan, F. Fallo et al., Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J. Clin. Endocrinol. Metab. 91, 2618-2623 (2006)
28. O. Olivieri, A. Ciacciarelli, D. Signorelli et al., Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J. Clin. Endocrinol. Metab. 89, 4221-4226 (2004)
29. G. Yin, S. Zhang, L. Yan, M. Wu, M. Xu, F. Li, H. Cheng, Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups. Endocrine 42, 182-189 (2012)
30. B.J. Gallay, S. Ahmad, L. Xu, B. Toivola, R.C. Davidson, Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37, 699-705 (2001)
31. O. Olivieri, F. Pizzolo, R. Corrocher, Aldosterone to renin ratio (ARR) in clinical use, with reference to the primary care setting: ARR to whom, when, how, what for? Curr. Hyper. Rev. 4, 227-233 (2008)
32. G.L. Schwartz, S.T. Turner, Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin. Chem. 51, 386-394 (2005)
33. F. Pizzolo, R. Raffaelli, A. Memmo et al., Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J. Clin. Endocrinol. Metab. 28, 135-142 (2010)
34. J.W. Funder, Aldosterone and mineralcorticoid receptors: a personal reflection. Mol. Cell. Endocrinol. 350, 146-150 (2012)
35. F. Fallo, F. Veglio, C. Bertello et al., Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91, 454-459 (2006)
36. G. Iacobellis, L. Petramala, D. Cotesta et al., Adipokines and cardiometabolic profile in primary aldosteronism. J. Clin. Endocrinol. Metab. 95, 2391-2398 (2010)
37. A.H. Ahmed, R.D. Gordon, P.J. Taylor, G. Ward, E. Pimenta, M. Stowasser, Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J. Clin. Endocrinol. Metab. 96, E 340-E 346 (2011)